Biopharma
ByDid Cardiovascular Approvals in 2025 Signal a New Era in Heart Disease Management—and Set the Pace for 2026 Innovation?
Global – December 2025 — The cardiovascular (CV) therapeutic area re-emerged as a strategic growth engine in 2025,…
Did Infectious Disease Approvals in 2025 Redefine Global Preparedness—and Set the Course for Innovation in 2026?
Global – December 2025 — The infectious diseases (ID) landscape underwent a structural recalibration in 2025, shaped by…
Did Neuroscience Approvals in 2025 Mark a Turning Point—and Set the Stage for a Breakout Year in 2026?
Global – December 2025 — The neuroscience sector experienced a long-anticipated resurgence in 2025, driven by regulatory approvals…
Did Immunology Approvals in 2025 Redefine Autoimmune Care—and Set the Stage for a New Growth Cycle in 2026?
Global – December 2025 — The immunology sector entered a decisive transformation in 2025, marked by major regulatory…
Is Strategic Out-Licensing the Fastest Path to Global Scale? Restari Secures $230 Million PDE-5 Deal with AriBio
23 January 2026 Executive Summary Restari has secured exclusive global out-licensing rights from AriBio for a next-generation PDE-5…
Is GSK Buying Its Way Past the Patent Cliff? $2.2 Billion Rapt Therapeutics Deal Signals Pipeline Reset
January 2026 Executive Summary GSK has agreed to acquire Rapt Therapeutics, a U.S.-based biotech focused on inflammatory and…
